Trial · NCT06178588
Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma
NCT06178588, Phase 2, Active not recruiting, University of Kansas Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma. Trials, record NCT06178588. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06178588
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma
- NCT number
- NCT06178588
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 15 participants, actual
- Lead sponsor
- University of Kansas Medical Center
- Conditions
Locally Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Recurrent Cholangiocarcinoma, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Sacituzumab Govitecan
- First posted
- 2023-12-21
- Last updated
- 2026-02-24
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall response rate | From start of treatment, up to 2 years | Defined as best response recorded from the start of the treatment until the end of treatment (taking into account any requirement for confirmation). Measured by computed tomography (CT) (magnetic resonance imaging \[MRI\] if CT contraindicated) Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Will be reported as a proportion with corresponding 90% confidence interval. |
| Secondary | Incidence of adverse events | From enrollment to 30 days after last administration of study treatment | Measured by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. |
| Secondary | Anti-tumor activity: Duration of response | From enrollment to end of follow up, up to 2 years | Measured by RECIST 1.1 |
| Secondary | Anti-tumor activity: Disease control rate | From enrollment to end of follow up, up to 2 years | Measured by RECIST 1.1 |
| Secondary | Progression free survival | From start of treatment until objective tumor progression or death, up to 2 years | Measured by survival curve and the medical record. Will be reported using Kaplan Meier estimates of the median along with a 90% confidence interval. |
| Secondary | Overall survival | From start of treatment to death, up to 2 years | Measured by survival curve and the medical record. Will be reported using Kaplan Meier estimates of the median along with a 90% confidence interval. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA168524 | The University of Kansas Cancer Center | JENSEN, ROY A. | UNIVERSITY OF KANSAS MEDICAL CENTER | NATIONAL CANCER INSTITUTE | 2012 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06178588
GET https://conductscience.org/api/trials/v1/NCT06178588/registered